Cidofovir ILIs were prepared by diluting a vial of cidofovir 375 mg in 60 ml of 0.9% sodium chloride, obtaining a final concentration of 6.25 mg/ml. Of these 60 ml, 5 syringes of 12 ml were loaded (75 mg of cidofovir in each one), which have a stability of 5 months refrigerated (2-8°C), according previous studies.Intralesional cidofovir treatment started in February 2022. After three drug administrations, a significant improvement in lesions was described by a reduction in both their volume and extension. A bad odor of superficial exudate was also reported, which was solved with first polymyxin and later fusidic acid, both administered topically, twice a day. The patient presented good tolerance to injections, only requiring local anesthesia with lidocaine for pain. Conclusion and RelevanceThis is the first case of use of this formulation of cidofovir ILIs in a patient with anogenital condylomatosis and immune deficiency. Previously, it was used in other manifestations of HPV infection. The formulation also proved to be stable, well-tolerated, and easy to prepare. Therefore, this therapy may be considered a reasonable option for the treatment of HVP condylomatosis when other treatments seem ineffective.

the mortality risk is being assessed but not registered in clinical charts.

No abstract

Background and Importance The opening of a pharmaceutical care service for onco-haematology patients (OHP) in the midst of the health care crisis caused by the COVID19 pandemic, made it possible to maintain the healthcare activity, avoid the collapse and provide the opportunity to implement Comprehensive Medication Management (CMM). Aim and Objectives To investigate the pharmacotherapeutic experience of OHP in outpatient therapy with CMM services; to know important aspects perceived for the identification of barriers/facilitators that determine the quality of the service and proposals for improvement. Material and Methods Descriptive observational design with a qualitative approach, using informal and semi-structured indepth interviews (participant observation and peer review) during January-June 2021. ATLAS.ti software was used for content analysis. Oncohaematology patients in outpatient therapy with any medication-related problem and who received CMM services were interviewed. Those who, due to cognitive limitation, could not be interviewed or who did not have a caregiver/family member available were excluded. Results 19 interviews were conducted: 57.89% patients and 42.10% caregivers; 57.89% were women. All patients were very satisfied with the care received, the vast majority preferred to be attended by a pharmacist, and valued telepharmacy as an alternative or complementary option. The vision of the pharmacy professional as an expert in medicines improves. They suggest improvement related to location, waiting times and greater accessibility of the pharmacist. After the researchers' reflective process, were identified as barriers: care pressure, limited time/resources, lack of interlevel coordination, and facilitators: prioritisation of interventions, integration of pharmacist in the multidisciplinary team, trust in the pharmacist and the new model of care. Improvement strategies: provision of human/material resources with release of pharmacist's time to provide the CMM, extension of hours, information management with the development of personal learning environment and use of programs for recording/integration of information and interventions. Conclusion and RelevanceDelving into patients' experiences can be key to improving the quality of care. In our case, the implementation of the CMM service in OHP has been a challenge and an opportunity in the current context of the COVID-19 pandemic. The pharmacy adapted to the needs and implemented a new model of care with excellent acceptance by users.

Aim and Objectives To evaluate the efficiency of simplification to bitherapy with DTG/3TC or with DTG/RPV in patients with HIV. Material and Methods Observational, retrospective study, carried out in a second-level hospital from July 2019 to March 2022. All patients diagnosed with HIV who simplified antiretroviral treatment to bitherapy with DTG/3TC or DTG/RPV were included.The main variables studied were the percentage of patients with undetectable viral load (viral load <50 copies/mL) measured in the first analytical determination performed after treatment simplification and the economic impact of this simplification.Other variables recorded were age, sex, viral load prior to treatment simplification, and type of bitherapy received.The data was obtained from the electronic medical record and the pharmacy dispensing program.Statistical data analysis was performed using descriptive frequency analysis.For the analysis of the economic impact, the difference between the annual consumption of each patient in treatment with triple therapy and with bitherapy was calculated. Results 415 patients receiving antiretroviral treatment were in follow-up in our centre. Treatment simplification was performed on 154 patients (37.10%). 76.62% (118/154) were men. The median age was 45 years (22-87). Before the change in treatment, 98.7% (152/154) of patients had undetectable viral load. 96.1% (148/154) of patients had a new viral load determination after treatment simplification. This determination was made with a median follow-up of 5.33 months (1.5-12.76). Of these, 100% (148/148) of patients maintained undetectable viral load. In 94.81% (146/154) of patients, treatment was simplified to DTG/3TC and in 5.19% (8/154) to DTG/RPV. The economic impact of the simplification of treatment to bitherapy for 154 patients implies a saving of C ¼ 198,842.62/ year (C ¼ 179,352.64/year with simplification to DTG/3TC of 146 patients and C ¼ 19,489.98/year with simplification to DTG/RPV of eight patients). Conclusion and RelevanceThe simplification of antiretroviral treatment to bitherapy with DTG/3TC or DTG/RPV has proven to be a good treatment option in terms of efficiency: patients maintain undetectable viral load after simplification of therapy and this change translates into considerable savings. However, long-term clinical results need to be verified.